首页> 外文学位 >The design and synthesis of novel chalcogenopyrylium dyes as agents for photodynamic therapy.
【24h】

The design and synthesis of novel chalcogenopyrylium dyes as agents for photodynamic therapy.

机译:新型硫属吡啶鎓染料的设计与合成作为光动力治疗剂。

获取原文
获取原文并翻译 | 示例

摘要

Photodynamic therapy (PDT) has recently been developed as a chemotherapeutic treatment for cancer, especially in the treatment of cancers such as lung, bladder, esophageal, gastric and colon cancers. PDT involves the selective delivery of light to a tumor mass through the use of catheters and fiber optic cables. PDT employs a drug, known as a photosensitizer, which upon activation by light undergoes a chemical reaction to produce a cytotoxic agent in the tumor cell. The ideal photosensitizers for PDT are materials that can localize in and around the tumor mass, and are non-toxic to normal cells. These dyes must be activated by light at wavelengths greater than 700nm, where penetration of light into tissue is optimal. Furthermore, these materials must be chemically efficient in producing the cytotoxic agent. Such an agent would allow the selective destruction of tumor tissue while leaving normal tissue intact.; The objective of this project is to design and synthesize novel clinical agents that will be useful as sensitizers for PDT. The sensitizers prepared are dyes closely related in structure to known cationic sensitizers already used in PDT, such as AA1. Although these dyes have been examined as photosensitizers for PDT, they absorb light of wavelengths that are too short for good tissue penetration, and are inefficient at producing the cytotoxic agents. Our goal is to provide heavy-atom analogues of these dyes, in particular, telluropyrylium and selenopyrylium analogues. The replacement of specific light atoms (i.e. oxygen, sulfur) of the known photosensitizers with heavy-atom (i.e. selenium, tellurium) analogues will have a two-fold effect. First, the use of telluropyrylium and selenopyrylium analogues should increase the wavelength of absorption of the photosensitizers. Second, telluropyrylium and selenopyrylium are more efficient at producing the cytotoxic agent singlet oxygen. These modifications will create photosensitizers for PDT.
机译:近来,光动力疗法(PDT)已被开发为用于癌症的化学疗法,特别是在诸如肺癌,膀胱癌,食道癌,胃癌和结肠癌的癌症的治疗中。 PDT涉及通过使用导管和光纤电缆将光选择性地传递到肿瘤块。 PDT使用一种称为光敏剂的药物,该药物在被光激活后会发生化学反应,从而在肿瘤细胞中产生细胞毒剂。用于PDT的理想光敏剂是可以定位在肿瘤块内部和周围并且对正常细胞无毒的材料。这些染料必须被大于700nm的波长的光激活,在这种情况下,光最好穿透组织。此外,这些材料在产生细胞毒性剂方面必须在化学上有效。这样的试剂将允许肿瘤组织的选择性破坏,同时保持正常组织完整。该项目的目的是设计和合成可用作PDT敏化剂的新型临床药物。制备的敏化剂是染料,其结构与PDT中已使用的已知阳离子敏化剂(如AA1)密切相关。尽管已经检查了这些染料作为PDT的光敏剂,但它们吸收的波长太短而无法良好地穿透组织,并且在产生细胞毒性剂方面效率不高。我们的目标是提供这些染料的重原子类似物,尤其是碲吡啶鎓和硒吡啶鎓类似物。用重原子(即硒,碲)类似物代替已知光敏剂中的特定轻原子(即氧,硫)将产生双重效果。首先,碲化吡啶鎓和硒化吡啶鎓类似物的使用应增加光敏剂的吸收波长。第二,碲化pyrypyrylium和selenopyrylium更有效地产生细胞毒剂单线态氧。这些修改将创建用于PDT的光敏剂。

著录项

  • 作者

    Leonard, Kristi Anne.;

  • 作者单位

    State University of New York at Buffalo.;

  • 授予单位 State University of New York at Buffalo.;
  • 学科 Chemistry Pharmaceutical.
  • 学位 Ph.D.
  • 年度 2000
  • 页码 139 p.
  • 总页数 139
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药物化学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号